Can't find the products you're looking for? Try to filter in the left sidebar.Filter By Tag
Our customer service representatives are available 24 hours a day, from Monday to Sunday. Contact Us
For Research Use Only. Not For Clinical Use.
Creative Biolabs provides a comprehensive portfolio of premium anti-GCGR recombinant antibodies, meticulously developed and manufactured to the highest quality standards. Our robust platforms and stringent quality control processes ensure the reliability and efficacy of these antibodies, making them indispensable tools for researchers exploring the intricate role of GCGR in diverse biological processes.
GCGR, a critical regulator of glucose homeostasis, plays a pivotal role in maintaining blood sugar levels by stimulating glycogen breakdown and gluconeogenesis. Excessive activation of GCGR, often linked to hyperglucagonemia, has been implicated in hyperglycemia. Given the promising results from preclinical and early clinical studies targeting GCGR, this receptor emerges as a compelling therapeutic target for the treatment of diseases associated with dysregulated glucose metabolism.
Glucagon receptor; GGR; GL-R; MVAH.
FDA approved drug targets, G-protein coupled receptors, Plasma proteins, Transporters
Intracellular, Membrane (different isoforms)
Cell type enriched (Hepatocytes)
Not detected in immune cells
Cell line enhanced (HeLa, MCF7, SK-BR-3, U-87 MG)
G-protein coupled receptor, Receptor, Transducer
Creative Biolabs offers a comprehensive suite of high-quality anti-GCGR recombinant antibodies, meticulously engineered to deliver exceptional performance, specificity, and sensitivity. Our antibodies are available in various formats to accommodate a broad spectrum of research applications, such as WB, ELISA, FC, etc. Backed by our robust platforms and rigorous quality control processes, our anti-GCGR antibodies provide reliable and reproducible results, empowering researchers to delve deeper into the intricate role of GCGR in health and disease.
Table 1. Featured anti-GCGR recombinant antibody products at Creative Biolabs.
Cat. No. | Product Name | Target Species | Host Species | Applications |
TAB-068CQ | Human Anti-GCGR Recombinant Antibody (TAB-068CQ) | Human, Cynomolgus monkey, Mouse, Rat | Human IgG2 | ELISA, FC |
ZG-0142U | Human Anti-GCGR Recombinant Antibody (clone 9G1) | Human | Humanized IgG1 | ELISA |
HPAB-0138-FY | Human Anti-GCGR Recombinant Antibody (HPAB-0138-FY) | Human | Human IgG4, κ | Block |
HPAB-0105LY | Human Anti-GCGR Recombinant Antibody (HPAB-0105LY) | Human | Human IgG | ELISA |
HPAB-1620LY | Human Anti-GCGR Recombinant Antibody (clone CBL034) | Human | Human IgG | ELISA, IHC |
Creative Biolabs adheres to rigorous quality control standards throughout the production process of anti-GCGR recombinant antibodies. Our comprehensive quality assurance procedures involve state-of-the-art analytical techniques, stringent testing protocols, and meticulous documentation to ensure the purity, specificity, potency, and lot-to-lot consistency of our products. This commitment to quality enables researchers to rely on our anti-GCGR antibodies for accurate and reproducible results in their scientific investigations.
Fig.1 ELISA analysis of anti-GCGR antibody
(Cat# ZG-0142U, Creative Biolabs).
Fig.2 SDS-PAGE analysis of anti-GCGR antibody
(Cat# TAB-068CQ, Creative Biolabs).
Fig.3 HPLC analysis of anti-GCGR antibody
(Cat# TAB-068CQ, Creative Biolabs).
Creative Biolabs employs cutting-edge genetic engineering technology to manufacture high-quality anti-GCGR recombinant antibodies on a flexible scale. Our robust platforms ensure precise design, optimization, and expression, enabling constant performance and dependability to meet customers’ various demands.
Featured Anti-GCGR Recombinant Antibody Production Platforms
Fig.4 Milligram-scale anti-GCGR recombinant antibody production.
Fig.5 Gram-scale anti-GCGR recombinant antibody production.
Creative Biolabs provides a comprehensive suite of high-quality anti-GCGR recombinant antibodies to cater to the diverse research needs of scientists worldwide.
Fig.6 Full-length anti-GCGR recombinant antibody production and modalities.
Table 2. Public drug targeting GCGR.
Company | Research Phase | Classification | Condition |
Lilly Locemia Solutions (Originator) |
Launched - 2019 |
Glucagon Polypeptides, from 10 AA to 40 AA Recombinant proteins |
Diabetes Diabetes type 1 Diabetes type 2 Hypoglycemia |
Bedford (Hikma) Eisai Hikma Novo Nordisk (Originator) Paladin |
Launched - 1993 |
Glucagon Polypeptides, from 41 AA Recombinant proteins |
Gastrointestinal Disorders Hypoglycemia |
Hanmi (Originator) | Phase II |
Fc Fusion Proteins Glucagon Analogues Pegylated Drugs Polypeptides, from 41 AA |
Hyperinsulinemia Hypoglycemia Obesity |
Ionis Pharmaceuticals (Originator) Isis Pharmaceuticals (Ionis Pharmaceuticals) Suzhou Ribo Life Science |
Phase II |
Antisense Therapy Single-stranded oligodeoxyribonucleotide (DNA) |
Diabetes type 2 |
Amgen (Originator) Duke University REMD Biotherapeutics |
Phase II | Human Monoclonal Antibodies |
Diabetes type 1 Diabetes type 2 Hyperglycemia |
NGM Biopharmaceuticals (Originator) | Phase I | Humanized Monoclonal Antibodies | Diabetes |
Lilly (Originator) | Phase I | Humanized Monoclonal Antibodies | Hyperglycemia |
Regeneron (Originator) | Phase I | Human Monoclonal Antibodies | Diabetes type 2 |
Ionis Pharmaceuticals (Originator) Isis Pharmaceuticals (Ionis Pharmaceuticals) ISIS Pharma (Pfizer) Ortho-McNeil (Janssen) Ortho-McNeil-Janssen (Janssen) |
Phase I |
Antisense Therapy Oligonucleotides |
Diabetes Diabetes type 2 |
Peking University Third Hospital (PUTH) (Originator) REMD Biotherapeutics (Originator) |
Preclinical | Human Monoclonal Antibodies | Diabetes type 2 |
(Disclaimer: The information in this table is just for knowledge sharing and not for marketing or sales purposes.)
To delve deeper into the capabilities of Creative Biolabs' high-quality anti-GCGR recombinant antibodies, please reach out to us at your convenience. We are committed to providing comprehensive solutions and support to researchers worldwide.